The purpose of this real-world investigation was to characterize the rate of EGFR testing among individuals diagnosed with de novo metastatic NSCLC in Alberta, Canada between 2013–2019 and to describe the prevalence, treatment patterns, and outcomes of those who had Exon19, L858R, and Exon20ins mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.